

Evaluation of Serum Vitamin D  
Level in Vitiligo Patients with  
and without Autoimmune Diseases

*Thesis*

*Submitted for partial fulfillment of Master Degree in  
Dermatology, Venereology and Andrology*

By

**Heba-tullah M. Magdy M. Hamza**

(M.B., B.Ch.)

Faculty of Medicine - Ain Shams University

Under Supervision of

**Prof. Dr. Hanan M. Ahmed Saleh**

*Professor of Dermatology, Venereology & Andrology*

*Faculty of Medicine - Ain Shams University*

**Dr. Nermeen Samy Abdel Fattah**

*Assistant Professor of Dermatology, Venereology & Andrology*

*Faculty of Medicine - Ain Shams University*

**Faculty of Medicine**

**Ain Shams University**

**2011**

## الملخص العربى

تقييم مستوى فيتامين د فى الدم لدى مرضى البهاق مع  
وبدون أمراض المناعة الذاتية

رسالة

توطئة للحصول على درجة الماجستير فى الامراض  
الجلدية و التناسلية و أمراض الذكورة

مقدمة من

**الطبيبة/ هبة الله محمد مجدى محمد حمزه**

بكالوريوس الطب و الجراحة  
كلية الطب – جامعة عين شمس

تحت اشراف

**الأستاذ الدكتور/ حنان محمد أحمد صالح**

أستاذ الامراض الجلدية و التناسلية و امراض الذكورة  
كلية الطب – جامعة عين شمس

**الدكتور / نيرمين سامى عبد الفتاح**

أستاذ مساعد الامراض الجلدية و التناسلية و أمراض الذكورة  
كلية الطب – جامعة عين شمس

كلية الطب

جامعة عين شمس

2011

## Summary

Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis that gives rise to well defined white patches which are often symmetrically distributed. It occurs worldwide in about 0.1-2% of different population and it occurs as frequently in males as it does in females. The cause is unknown, but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors.

Vitiligo reflects a systemic process that has important implications beyond the skin. These include other autoimmune diseases and ocular and neurological abnormalities. Vitiligo is commonly associated with systemic autoimmune conditions, including hypothyroidism and hyperthyroidism, diabetes mellitus, and Sjogren's syndrome.

In our study, we aimed to evaluate serum vitamin D levels in vitiligo patients with and without autoimmune diseases in comparison to healthy controls.

Vitamin D is a secosteroid hormone that regulates the growth and differentiation of multiple cell types, and displays immunoregulatory and anti-inflammatory properties. In the skin calcitriol regulates the growth of epidermal cells by inhibiting proliferation and inducing terminal differentiation of keratinocytes, and enhances immunosuppressive and anti-inflammatory pathways.

# *Table of Contents*

Title	Page No.
<b>INTRODUCTION</b>	<b>1</b>
<b>AIM OF THR WORK</b>	<b>3</b>
<b>REVIEW OF LITERATURE</b>	
<b>Chapter 1: Vitiligo</b>	<b>4</b>
1.1 Definition	<b>4</b>
1.2 Nomenclature and Historical Background	<b>4</b>
1.3 Epidemiology	<b>5</b>
1.4 Genetics	<b>6</b>
1.5 Precipitating Factors	<b>9</b>
1.6 Pathogenesis	<b>10</b>
1.7 Clinical Features	<b>17</b>
1.8 Clinical Classification of Vitiligo	<b>18</b>
1.9 Systemic Association	<b>20</b>
<b>Chapter 2: Vitamin D</b>	
2.1 Introduction	<b>26</b>
2.2 Forms of Vitamin D	<b>26</b>
2.3 Sources of Vitamin D	<b>27</b>
2.4 Metabolism of vitamin D	<b>27</b>
2.5 Level of vitamin D in adult serum	<b>30</b>
2.6 Limiting Factors of Cutaneous Vitamin D Synthesis	<b>30</b>
2.7 Vitamin D Receptor	<b>32</b>
2.8 Role of vitamin D in normal skin	<b>33</b>
2.9 Role of vitamin D in skin diseases	<b>36</b>
2.10 Vitamin D and autoimmunity	<b>38</b>
<b>SUBJECTS AND METHODS</b>	<b>43</b>
<b>RESULTS</b>	<b>49</b>
<b>DISCUSSION</b>	<b>66</b>
<b>SUMMARY</b>	<b>71</b>
<b>CONCLUSION AND RECOMMENDATIONS</b>	<b>73</b>
<b>REFERENCES</b>	<b>75</b>
<b>ARABIC SUMMARY</b>	<b>--</b>

## *List of Figures*

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
<b>1</b>	Summary of the possible cellular and humoral immune mechanisms of vitiligo	<b>13</b>
<b>2</b>	Pathway of vitamin D synthesis	<b>29</b>
<b>3</b>	Vitamin D sources, metabolism, mechanism of action and biological functions	<b>29</b>
<b>4</b>	The immunomodulatory effects of vitamin D	<b>40</b>
<b>5</b>	Comparison between cases and controls as regards occupation	<b>51</b>
<b>6</b>	Comparison between cases and controls as regards vitamin D intake/day	<b>52</b>
<b>7</b>	Comparison between cases and controls as regards special habits	<b>52</b>
<b>8</b>	Comparison between group 1 and 2 as regards onset of vitiligo	<b>56</b>
<b>9</b>	Comparison between group 1 and 2 as regards duration of vitiligo and affected BSA	<b>56</b>
<b>10</b>	Comparison between cases and controls as regards vitamin D level	<b>60</b>
<b>11</b>	Comparison between group 1 and 2 as regards vitamin D level	<b>61</b>
<b>12</b>	Comparison between occupation and vitamin D level among patients	<b>62</b>

## *List of Tables*

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
<b>1</b>	Types of vitiligo	<b>19</b>
<b>2</b>	Segmental versus non-segmental vitiligo	<b>20</b>
<b>3</b>	Reported coexisting disorders	<b>24</b>
<b>4</b>	Personal characteristics of patients	<b>49</b>
<b>5</b>	Personal characteristics of controls	<b>50</b>
<b>6</b>	Comparison between cases and controls as regards personal characteristics and vitamin D intake	<b>51</b>
<b>7</b>	Comparison between group 1 and 2 as regards personal characteristics and vitamin D intake	<b>53</b>
<b>8</b>	Clinical characteristics of vitiligo among patients	<b>54</b>
<b>9</b>	Comparison between group 1 and 2 as regards clinical characteristics of vitiligo	<b>55</b>
<b>10</b>	Family history of vitiligo and autoimmune diseases among patients	<b>57</b>
<b>11</b>	Comparison between group 1 and 2 as regards family history of vitiligo or autoimmune diseases	<b>58</b>
<b>12</b>	Description of type and duration of autoimmune diseases among Group 1	<b>58</b>
<b>13</b>	Comparison between cases and controls as regards vitamin D level	<b>59</b>
<b>14</b>	Comparison between group 1 and 2 as regards vitamin D level	<b>61</b>
<b>15</b>	Comparison between sex, occupation, special habits, vitamin D intake and vitamin D level among patients	<b>62</b>
<b>16</b>	Comparison between onset, course of vitiligo and vitamin D level among patients	<b>63</b>
<b>17</b>	Comparison between family history of vitiligo and autoimmune diseases with vitamin D level among patients	<b>63</b>
<b>18</b>	Comparison between personal history of autoimmune disease, type of autoimmune diseases and vitamin D level among patients	<b>64</b>
<b>19</b>	Correlations between age, duration of vitiligo, duration of autoimmune disease, affected body surface area (%) and vitamin D level among patients	<b>64</b>
<b>20</b>	Linear Regression analysis of multiple independent variables on vitamin D level (dependent variable)	<b>65</b>

## *List of Abbreviations*

<b>AD</b>	: Atopic dermatitis
<b>ADCC</b>	: Antibody-dependent cell cytotoxicity
<b>AISL</b>	: Autoimmune susceptibility locus
<b>AMPs</b>	: Antimicrobial peptides
<b>ANA</b>	: Antinuclear antibody
<b>ANOVA</b>	: Analysis of Variance
<b>Anti TG</b>	: Antithyroglobulin antibody
<b>Anti TPO</b>	: Antithyroid peroxidase antibody
<b>APC</b>	: Antigen presenting cell
<b>B</b>	: Regression coefficient
<b>BSA</b>	: Body surface area
<b>CAT</b>	: Catalase gene
<b>COMT</b>	: Catechol-O-methyl transferase
<b>CMV</b>	: Cytomegalovirus
<b>CPDs</b>	: Cyclobutane pyrimidine dimers
<b>CPM</b>	: Count per minute
<b>CTLA-4</b>	: Cytotoxic lymphocyte antigen 4
<b>DBP</b>	: Vitamin D binding protein
<b>DCs</b>	: Dendritic cells
<b>EBV</b>	: Epstein-Barr virus
<b>FGF</b>	: Fibroblast growth factors
<b>FOXP1</b>	: Forkhead box P1 gene
<b>H<sub>2</sub>O<sub>2</sub></b>	: Hydrogen peroxide
<b>HBD</b>	: Human beta-defensin
<b>HCV</b>	: Hepatitis C virus
<b>HIV</b>	: Human immunodeficiency virus
<b>HLA</b>	: Human Leukocyte Antigen
<b>HS</b>	: Highly significant
<b>IBD</b>	: Inflammatory bowel disease
<b>IFN-<math>\gamma</math></b>	: Interferon gamma
<b>IKP</b>	: Isomorphic Koebner phenomenon
<b>IL-1</b>	: Interleukin-1
<b>IU</b>	: International units
<b>kDa</b>	: Kilo dalton
<b>MARRS</b>	: Membrane associated rapid response steroid binding
<b>MAP</b>	: Mitogen-activated protein
<b>MCHR1</b>	: Melanin-concentrating hormone receptor 1
<b>MHC</b>	: Major histocompatibility
<b>MS</b>	: Multiple sclerosis
<b>MYG1</b>	: Melanocyte proliferating gene 1
<b>N</b>	: Number
<b>NK</b>	: Natural killer

## *List of Abbreviations (Cont.)*

<b>NO</b>	: Nitric oxide
<b>NS</b>	: Non significant
<b>NSV</b>	: Non-segmental vitiligo
<b>P</b>	: Propability value
<b>PTH</b>	: Parathyroid hormone
<b>PTHrP</b>	: Parathyroid hormone-related peptides
<b>PUVA</b>	: Psoralen and ultraviolet rays
<b>r</b>	: Correlation coefficient
<b>RA</b>	: Rheumatoid arthritis
<b>Raf</b>	: Rapidly growing fibrosarcoma
<b>RIA</b>	: Radioimmunoassay
<b>S</b>	: Significant
<b>SD</b>	: Standard deviation
<b>SLE</b>	: Systemic lupus erythematosus
<b>SPF</b>	: Sunburn protective factor
<b>TCR</b>	: T-cell receptors
<b>Th1</b>	: T helper 1
<b>TNF-<math>\alpha</math></b>	: Tumor necrosis factor-alpha
<b>Treg</b>	: Regulatory T cells
<b>TRP</b>	: Tyrosinase-related protein
<b>TSH</b>	: Thyroid stimulating hormone
<b>TYR</b>	: Tyrosinase
<b>UK</b>	: United Kingdom
<b>UV</b>	: ultraviolet light
<b>VDR</b>	: Vitamin D receptor
<b>VKH</b>	: Vogt-Koyanagi-Harada
<b>1<math>\alpha</math>,25(OH)2D3</b>	: Calcitriol(1,25-dihydroxy-vitamin D3 , 1 $\alpha$ ,25-
<b>1,25(OH)2D3</b>	: dihydroxyvitamin D3)
<b>1<math>\alpha</math>-OHase or CYP27B1</b>	: 1 $\alpha$ hydroxylase or cytochrome P450 protein
<b>4-TBP</b>	: 4-tertiary butylphenol
<b>7DHC</b>	: 7-dehydrocholesterol
<b>24-OHase or CYP24A1</b>	: 24-hydroxylase
<b>25(OH)D</b>	: 25-hydroxyvitamin D
<b>%=</b>	: Percentage



## Introduction

Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis that gives rise to well defined white patches which are often symmetrically distributed. It occurs worldwide in about 0.1-2% of the population and it occurs as frequently in males as it does in females. The cause is unknown, but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors (*Njoo and Westerhof, 2001*).

Vitiligo is commonly associated with systemic autoimmune conditions, including hypothyroidism and hyperthyroidism, diabetes mellitus, and Sjogren's syndrome. Many autoimmune conditions have been found to be associated with reduced vitamin D levels, including rheumatoid arthritis (RA), diabetes mellitus, and multiple sclerosis (MS). However, little is known about the association between vitiligo and reduced vitamin D levels (*Sehgal et al., 1976; Niepomniszcze and Amad, 2001; Montes et al., 2003; Adorini and Penna, 2008*).

Vitamin D<sub>3</sub> can be obtained through the diet, but it is mainly biosynthesized from 7-dehydrocholesterol (7DHC) in skin exposed to ultraviolet (UV) light. Vitamin D<sub>3</sub> is hydroxylated in the liver to produce 25 hydroxy vitamin D<sub>3</sub> (25(OH)D<sub>3</sub>), a reliable indicator of vitamin D status, and is further hydroxylated in the kidney to form the active hormone calcitriol (1,25(OH)<sub>2</sub>D<sub>3</sub>). 1,25(OH)<sub>2</sub>D<sub>3</sub>, the biologically active form of vitamin D<sub>3</sub>, is a secosteroid hormone that regulates the growth and differentiation

of multiple cell types, and displays immunoregulatory and anti-inflammatory properties. Cells involved in innate and adaptive immune responses including macrophages, dendritic cells, T cells and B cells express the vitamin D receptor (VDR), and can both produce and respond to  $1,25(\text{OH})_2\text{D}_3$ . The net effect of the vitamin D system on the immune response is an enhancement of innate immunity coupled with multifaceted regulation of adaptive immunity (*Adorini and Penna, 2008*).

## **Aim of the work**

The aim of this work is to evaluate serum levels of vitamin D in vitiligo patients with and without autoimmune diseases.

# Vitiligo

## **1.1. Definition**

Vitiligo is divided into segmental and non-segmental forms. “Generalized vitiligo or non-segmental vitiligo (NSV) is an acquired chronic pigmentation disorder characterized by white patches, often symmetrical, which usually increases in size with time, corresponding to a substantial loss of functioning epidermal and sometimes hair follicle melanocytes” while “Segmental vitiligo is an acquired chronic pigmentation disorder characterized by white patches with a unilateral distribution that may totally or partially match a dermatome, but not necessarily. Other distribution patterns can be encountered that cross several dermatomes, or correspond to large areas delineated by Blaschko’s lines” (*Taïeb and Picardo, 2007*).

## **1.2. Nomenclature and Historical Background**

Vitiligo was observed very early in history, and most ancient civilizations and religions had some type of reference about lack of pigmentation (*Lahiri, 2009*).

Vitiligo is cited in many ancient writings. Indian literature dating to 1500 to 1000 BC refers to the word Kilas (“Kil” means white, “as” means to cast or throw away) and

palita (“pal” implies gray, old, and aged), referring to white patches on the skin (*Singh et al., 1974*).

The name vitiligo was first used by the famous Roman physician Celsus at the second century AD in his medical classic “De Medicina”. The word vitiligo has often been said to have derived from “vitium” (defect or blemish) rather than “vitellus” meaning calf (*Panda, 2005*).

In the Holy Koran, the word “baras”, meaning white skin, is used to describe a condition that Jesus cured (*Sharque, 1984*).

### **1.3. Epidemiology**

Vitiligo is the most prevalent pigmentary disorder that occurs worldwide with an incidence rate of between 0.1% and 2% (*Alkahateeb et al., 2003; Daneshpazhooh et al., 2006 and Torello et al., 2008*) irrespective of age, race (*Moretti et al., 2006 and Torello et al., 2008*) ethnic origin or skin color (*Whitton et al., 2008*). The prevalence has been reported as high as 4% in some South Asian, Mexican and United States populations (*Parsad et al., 2003; Sehgal and Srivastava, 2007*).

Almost half of the patients present before the age of 20 years, and nearly 70–80% before the age of 30 years. Adults and children of both sexes are equally affected, although larger number of females consult the doctor probably due to the

greater psycho-social perceived impact of the disease (*Sehgal and Srivastava, 2007*).

### **1.4. Genetics**

Genetic risk for vitiligo is well supported by multiple lines of evidence. Vitiligo is frequently associated with familial clustering (*Mehta et al., 1973; Carnevale et al., 1980; Goudie et al., 1983; Hafez et al., 1983; Das et al., 1985; Majumder et al., 1993 and Alkhateeb et al., 2003*) and 20% to 30% of patients with vitiligo have positive family history (*Passeron and Ortonne, 2005*). In addition, segregation analysis suggested that vitiligo is a multifactorial and polygenic disorder that likely results from multiple genetic and environmental factors (*Arcos-Burgos et al., 2002; Alkhateeb et al., 2003; Zhang et al., 2004 and Sun et al., 2006*).

There may in fact be two coexisting modes of inheritance for vitiligo depending on age of onset. In patients with early onset vitiligo (before the age of 30 years), vitiligo inheritance most closely followed a dominant mode of inheritance with incomplete penetration. However, a predisposition to vitiligo resulting from a recessive genotype and exposure to certain environmental triggers appeared to explain the inheritance pattern of late onset vitiligo (after 30 years of age) (*Huggins et al., 2005*).

Several Human Leukocyte Antigen (HLA) studies have been performed which showed sporadic association between vitiligo and certain HLA groups. Linkage and association studies have provided strong support for vitiligo susceptibility genes on chromosomes 1p31, 7q, 8p and 17p13 in Caucasian population and 4q13-q21, 6p21-p22-q27 and 22q12 in Chinese population (*Nath et al., 2001; Alkhateeb et al., 2002; Spritz et al., 2004; Chen et al., 2005; Liang et al., 2007 and Quan et al., 2010*).

Chromosome 1p31 has been found to be associated to a highly significant degree with generalized vitiligo in North American and United Kingdom (UK) whites. It is termed the autoimmune susceptibility locus (AISL), and it is responsible for susceptibility to autoimmunity, particularly vitiligo, whereas the presence of other genes (e.g., the major histocompatibility (MHC) locus on chromosome 6), combined with exposure to extrinsic or intrinsic factors, may mediate the occurrence of Hashimoto's thyroiditis in individuals who are AISL susceptible. This is the reason for the increased prevalence of Hashimoto's thyroiditis in patients with vitiligo, and it seems to be genetically determined (*Alkhateeb et al., 2002 and Alkhateeb et al., 2003*).

Catechol-O-methyl transferase (COMT) is an enzyme that plays a major role in the metabolism of toxic or biologically active drugs, neurotransmitters and metabolites. One such metabolite, O-quinones, can be formed during melanin synthesis in the absence of adequate COMT activity. A functional single-nucleotide polymorphism in the COMT gene was found to be associated